Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
August 2014, Vol 5, No 6
August 2014, Vol 5, No 6
Older Patients with AML Live Longer with Azacitidine
By
Robert Osborne
EHA 2014
,
EHA
August 2014, Vol 5, No 6
Milan, Italy—Older patients with acute myeloid leukemia (AML) gained a “clinically significant,” if not statistically significant improvement in survival when treated with azacitidine (Vidaza) rather than with conventional therapy, reported Hervé Dombret, MD, hematologist, Hôpital Saint Louis in Paris, France, at the European Hematology Association meeting.
Read Article
ASCO Issues Recommendations on How to Fix the 340B Drug Pricing Program
By
Lilly Ostrovsky, MS
Economics & Value
,
Pricing
August 2014, Vol 5, No 6
In April, the American Society of Clinical Oncology (ASCO) released a policy statement recommending how to fix the 340B Drug Pricing Program.
Read Article
The Long Road to Rehabilitation: Sandra Wade’s Story on Surviving Breast Cancer
By
Julie K. Silver, MD
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
,
The Patient Perspective
August 2014, Vol 5, No 6
Sandra Wade first e-mailed me on July 15, 2011. As you can see in the excerpts from her correspondence with me below, she asked me to contact her oncologist and let her know that as a breast cancer survivor, Sandra had suffered more than she should have, because she was not referred for rehabilitation services.
Read Article
Telephone-Based Cancer Care Support Program Saves Big Bucks
By
Kate O'Rourke
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Telephone-based support programs are capable of reducing cancer-related medical costs by 10% to 30%, according to results of the first nurse-led study of the cost impact of telephonic case management in oncology.
Read Article
Secondary Oncology Pathways Can Have Big Cost Impact
By
Kate O'Rourke
Economics & Value
,
Economics of Cancer Care
,
Pathways
August 2014, Vol 5, No 6
Chicago, IL—The implementation of collaborative, secondary clinical pathway programs can improve outcomes and can lower costs when providers are already participating in another payer-sponsored pathway program. This conclusion comes from a study published online in conjunction with the 2014 American Society of Clinical Oncology meeting.
Read Article
Patients with Cancer Are Not Asking for Low-Value Tests or Therapies
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Contrary to common belief, there appears to be little demand on the part of patients with cancer for unsuitable, high-cost, low-value tests or therapies.
Read Article
Most Hospital Readmissions Not Preventable for Patients with Cancer
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Hospital readmissions in patients with cancer reflect the high burden of this disease, which is often refractory and, therefore, readmission is not reasonably preventable.
Read Article
Oncologists Want More Education on How to Discuss Cost of Treatment with Patients
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Oncologists responding to a national electronic survey believe that discussing out-of-pocket (OOP) costs of therapy with patients is important, and that OOP costs and societal cost of therapy will play a larger role in cancer treatment decisions over the next 5 years.
Read Article
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
August 2014, Vol 5, No 6
Chicago, IL—Even after adjusted for improved outcomes, newer anticancer drugs are more expensive than older agents, said Rena Conti, PhD, Assistant Professor of Health Policy and Economics, University of Chicago, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Ibrutinib Receives Expanded Indication for Patients with CLL and 17p Deletion
FDA Approvals, News & Updates
August 2014, Vol 5, No 6
The FDA issued an expanded indication for ibrutinib (Imbruvica; Pharmacyclics) for the treatment of patients with CLL who have a deletion in chromosome 17 (17p deletion), which results in poor response to standard CLL therapies.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma